HCPLive Network

New Guidance Issued for Atrial Fibrillation

The American Heart Association (AHA), American College of Cardiology (ACC), and the Heart Rhythm Society (HRS) have issued updated guidelines on the management of patients with atrial fibrillation (AF) that include recommendations on new oral anticoagulants. The guidance replaces the previous full document released in 2006 and 2 focused updates from 2011.
 
The new guidelines rate dabigatran (Pradaxa), rivaroxaban (Xarelto), and apixaban (Eliquis) alongside warfarin as recommended for patients with nonvalvular AF with a history of stroke or transient ischemic attack or an otherwise elevated risk of stroke.
 
"Because what we say in the guideline can affect how a drug is used, we were careful to be even-handed and evidence-based in presenting new drugs," Craig T. January, MD, PhD, professor of Medicine in the Division of Cardiovascular Medicine at the University of Wisconsin-Madison, a fellow of the ACC, a member of the AHA and HRS, and chair of the writing committee, said in a statement. "Our goal was to provide useful, non-biased information."
 
For AF patients who have mechanical heart valves, the guidelines recommend warfarin, and the target International Normalized Ratio (INR) intensity (2.0 to 3.0 or 2.5 to 3.5) should be based on the type and location of the prosthesis.
 
The guidelines also advise clinicians use one of the newer anticoagulants for patients who can’t maintain a therapeutic INR between 2.0 and 3.0 on warfarin.
 
Dabigatran should not be used in patients with a mechanical heart valve, and dabigatran and rivaroxaban are not recommended for use in patients with end-stage chronic kidney disease or who are on hemodialysis.
 
Preferences were not provided for any of the 3 newer agents because there is a lack of head-to-head trials. Choice of antithrombotics should be based on shared decision making that considers risk factors, cost, tolerability, patient preference, potential for drug interactions, and other clinical characteristics.
 
The guidelines are to be published in the Journal of the American College of Cardiology, Circulation, Journal of the American Heart Association, and Heart Rhythm.



Further Reading
Patients are receiving medical implants that may not have been rigorously tested before or after their approval by the US Food and Drug Administration, two new studies contend. The findings were published online Sept. 29 in JAMA Internal Medicine.
Having trainee physicians review cases prior to clinic hours can reduce patient waiting times, flow times, and clinic session times, according to a study published online Sept. 16 in Pain Medicine. The management process studied was first popularized by Toyota in Japan.
Resistant hypertension is common among patients with type 2 diabetes, and is strongly associated with microvascular disease.
In this installment, we look at underlying causes of metabolic acidosis, approaches for evaluating patients with suspected metabolic acidosis, and why measurement of the anion gap is of great usefulness in these cases.
For critically ill cardiac surgery patients, fenoldopam does not reduce the need for renal replacement therapy, according to a study published online Sept. 29 in the Journal of the American Medical Association. The study was published to coincide with the annual meeting of the European Society of Intensive Care Medicine, held from Sept. 27 to Oct. 1 in Barcelona, Spain.
Researchers have withdrawn one of the previous Choosing Wisely recommendations from April 2012, according to a report from the American College of Cardiology.
Personal health is a global concern and 3 initiatives are being developed to encourage positive change, according to a report from the American Medical Association.
More Reading